6505--Carbidopa/Levodopa SA Tablet
ID: 36E79725R0008Type: Solicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/99fd2706b5bf47cdbf7ab1a2002c03a7/view
Timeline
  1. 1
    Posted Jan 16, 2025, 12:00 AM UTC
  2. 2
    Updated Jan 16, 2025, 12:00 AM UTC
  3. 3
    Due Jan 30, 2025, 8:30 PM UTC
Description

The Department of Veterans Affairs is seeking pharmaceutical suppliers to establish a national contract for the provision of Carbidopa/Levodopa SA tablets through its Pharmaceutical Prime Vendor program. The Request for Proposal (RFP) outlines specific requirements for potential contractors, including pricing structures for the base year and four option years, compliance with the Drug Supply Chain Security Act, and the necessity for Good Manufacturing Practices (cGMP) status. This procurement is crucial for ensuring a reliable supply of essential medications for veteran and military healthcare systems across the nation. Interested parties should contact Contract Specialist Christopher Carthron at Christopher.Carthron@va.gov for further details regarding the proposal submission process and deadlines.

Point(s) of Contact
Christopher CarthronContract Specialist
Christopher.Carthron@va.gov
Files
Title
Posted
36E79725R0008_1.docx
Dec 12, 2024, 10:06 PM UTC
The Department of Veterans Affairs (VA) plans to issue Request for Proposal (RFP) 36E79725R0008 for Carbidopa/Levodopa sustained release (SA) tablets, indicating an unrestricted procurement to supply various federal health services, including the Department of Defense and the Bureau of Prisons. The awarded contract will ensure a continuous supply of these medications for one year, with the possibility of extending for four additional yearly periods. Offerors must provide unique branding and packaging without overlapping labels. The electronic solicitation is expected to be issued around January 3, 2026, with offers due by January 17, 2026. Estimated annual usage totals approximately 119,875 bottles split between two dosage forms. All details and updates regarding the proposal will be available exclusively on sam.gov, with no paper copies distributed. Interested parties are encouraged to direct questions to the designated contracting officer, Chris Carthron.
36E79725R0008.docx
Jan 16, 2025, 10:06 PM UTC
The document outlines a Request for Proposal (RFP) from the Department of Veterans Affairs (VA) for pharmaceutical suppliers. The purpose is to establish a national contract for the provision of specific drug products, namely Carbidopa/Levodopa tablets, through its Pharmaceutical Prime Vendor (PPV) program. The RFP stipulates requirements for potential contractors, including pricing structures for the base year and four option years, product registration details, specific drug codes (NDCs), and compliance with the Drug Supply Chain Security Act (DSCSA). Additionally, the document emphasizes that contractors must have an acceptable Good Manufacturing Practices (cGMP) status and maintain manufacturer consistency throughout the contract period. Key details include the necessity for a Letter of Commitment from manufacturers or distributors, requirements for invoicing, quarterly sales reporting, and documenting contract compliance. The implementation period and delivery expectations are clearly defined, along with procedures for handling recalls and nonconformance issues. By outlining these parameters, the RFP reflects the VA’s commitment to ensuring a reliable drug supply at negotiated prices for veteran and military healthcare systems nationwide.
Lifecycle
Title
Type
6505--Carbidopa/Levodopa SA Tablet
Currently viewing
Solicitation
6505--Carbidopa/Levodopa SA Tablet
Presolicitation
Similar Opportunities
6505--Loperamide Capsules (VA-25-00032225)
Buyer not available
The Department of Veterans Affairs is seeking proposals for the procurement of Loperamide Hydrochloride capsules, aimed at establishing a reliable supply source for pharmaceutical products. This solicitation includes a base year and four one-year option periods, requiring bidders to submit unique National Drug Codes (NDC) and demonstrate compliance with Good Manufacturing Practices (cGMP) as certified by the FDA. The contract is crucial for ensuring the distribution of essential pharmaceuticals to VA facilities, the Department of Defense, and other government health service providers, emphasizing safety, quality, and regulatory compliance. Interested parties should contact Contract Specialist Andrew J. Cazares at Andrew.Cazares@va.gov for further details regarding the submission process and requirements.
6505--Topiramate Tablets (VA-25-00047941)
Buyer not available
The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Topiramate Tablets, designated as Solicitation 36E79725R0031. This procurement aims to secure an uninterrupted supply of various forms of Topiramate for the VA, Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS), highlighting the importance of ensuring continuous access to essential pharmaceuticals across federal health services. The contract will span one year with four additional pre-priced option years, and interested vendors must submit their proposals electronically by April 29, 2025, while providing the exact name of the drug along with a unique National Drug Code (NDC). For further inquiries, vendors can contact Contract Specialist Billy Fong at billy.fong@va.gov or by phone at 708-786-4992.
6505--Aprepitant Capsules
Buyer not available
The Department of Veterans Affairs is soliciting proposals for the supply of Aprepitant capsules, a pharmaceutical product essential for various government health facilities, including those under the Department of Defense and Indian Health Service. Offerors are required to provide pricing for multiple line items covering a base year and four option years, adhering to specific conditions such as a 0.5% Cost Recovery Fee and compliance with the Drug Supply Chain Security Act (DSCSA). The contract emphasizes the importance of maintaining current Good Manufacturing Practices (cGMP) and ensuring proper labeling and packaging of the products. Interested contractors should contact Contract Specialist Matthew S. Poulin at Matthew.Poulin@va.gov for further details and must submit their proposals in accordance with the outlined requirements.
6505--Perphenazine Tablets (VA-25-00037353)
Buyer not available
The Department of Veterans Affairs (VA) is soliciting proposals for the procurement of Perphenazine tablets under solicitation number VA-25-00037353. This contract aims to supply specified quantities of the drug to both the VA and the Department of Defense (DoD) through their Pharmaceutical Prime Vendor (PPV) Programs, with a focus on service-disabled veteran-owned small businesses, women-owned small businesses, and HUBZone small businesses. The procurement is critical for ensuring a consistent supply of pharmaceutical products while adhering to regulatory requirements, including the Drug Supply Chain Security Act (DSCSA) and FDA Good Manufacturing Practices (cGMP). Interested offerors must contact Contract Specialist Anthony DiCrescenzo at Anthony.DiCrescenzo@va.gov for further details, and proposals must include a 0.5% Cost Recovery Fee and a unique National Drug Code (NDC) for each product.
6505--Ranolazine Sustained Action (SA) Tablets
Buyer not available
The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Ranolazine Sustained Action (SA) Tablets, which will serve various federal entities, including the VA, Department of Defense, and Bureau of Prisons. The procurement aims to secure an uninterrupted supply of these pharmaceutical products, with specific requirements for labeling and packaging, including the necessity for a unique National Drug Code (NDC) and safety-cap standards. The estimated annual demand includes 229,028 bottles of 500 mg SA tablets and 95,925 bottles of 1000 mg SA tablets, with the contract expected to last one year, plus four optional one-year extensions. Interested offerors should monitor SAM.gov for updates and submit their proposals by May 6, 2025, with any inquiries directed to Contract Specialist Deb Fassl at Deborah.Fassl@va.gov.
6505--Fludrocortisone Acetate Tablets (VA-25-00047932)
Buyer not available
The Department of Veterans Affairs is soliciting bids for the procurement of Fludrocortisone Acetate Tablets (0.1 MG) under the VA & DoD Pharmaceutical Prime Vendor Programs. Contractors are required to submit proposals that include pricing for a base year and four option years, adhering to specific guidelines such as a 0.5% Cost Recovery Fee and compliance with the Drug Supply Chain Security Act. This procurement is crucial for ensuring a consistent supply of essential pharmaceuticals to veterans, emphasizing the importance of Good Manufacturing Practices (cGMP) and the need for a unique National Drug Code (NDC) for each product offered. Interested contractors should contact Youlanda Duggar at youlanda.duggar@va.gov for further details and to ensure compliance with all submission requirements.
6505--770-25-3-801-0361 -National CMOP MYCOPHENOLATE MOFETIL 250MG CAP -(VA-25-00060549)
Buyer not available
The Department of Veterans Affairs is seeking qualified vendors to supply Mycophenolate Mofetil 250mg capsules under solicitation number VA-25-00060549. The procurement requires vendors to submit their quotes, including a signed SF1449 solicitation cover page, an Excel quote spreadsheet, and documentation proving they are authorized dealers or distributors, by April 11, 2025. This pharmaceutical product is critical for patient care within the VA medical system, and all supplies must comply with the Drug Supply Chain Security Act, ensuring quality and traceability. Interested vendors should contact Contract Specialist Larry M Zaritz at larry.zaritz@va.gov for further details and clarification on submission requirements.
6505--760-25-1-050-0237 -Leavenworth CMOP OM PHARMACEUTICALS -(VA-25-00028391)
Buyer not available
The Department of Veterans Affairs (VA) is preparing to issue a request for proposal (RFP) for the procurement of fourteen specified pharmaceuticals to be delivered to the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) facility in Kansas. This opportunity is exclusively set aside for small businesses under the product service code 6505, which pertains to drugs and biologicals, and requires interested vendors to submit a price schedule, a signed SF1449 cover page, valid state wholesale distributor licenses, and a Buy American Act certificate. The procurement is crucial for ensuring that veterans receive timely access to necessary pharmaceuticals, with the estimated RFP issue date set for March 6, 2025, and a response deadline of March 17, 2025. Interested parties should direct their submissions and inquiries to Contracting Officer Kelley Cunningham at kelley.cunningham@va.gov or by phone at 913-684-0140.
760-25-1-050-0154 -Leavenworth CMOP THYROID TABLETS -(VA-25-00022614)
Buyer not available
The Department of Veterans Affairs is soliciting proposals for the procurement of Armour Thyroid tablets for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) under solicitation number 36C77025Q0079. This Request for Quotation (RFQ) emphasizes the need for specific brand-name pharmaceuticals, with a focus on compliance with federal regulations, including the Drug Supply Chain Security Act and the Buy American Act. The procurement process aims to ensure a reliable supply of essential medications for veterans, with a firm-fixed-price contract expected to be awarded based on fair market evaluations. Interested vendors must submit their quotes by December 27, 2024, at 4:00 PM CST, and can direct inquiries to Jennifer L. Knight at jennifer.knight@va.gov or by phone at 913-684-0162.
6505--770_Pharmaceuticals_VA CMOP National Office_36C77025Q0196 770-25-3-801-0371 -National CMOP A1222 ACAMPROSATE TAB
Buyer not available
The Department of Veterans Affairs is seeking vendors to provide Acamprosate Calcium 333mg EC tablets under solicitation number 36C77025Q0196 for delivery to multiple Consolidated Mail Outpatient Pharmacy (CMOP) facilities. The procurement includes specific quantities of the pharmaceuticals, with a total of six different shipment requirements outlined, emphasizing compliance with the Drug Supply Chain Security Act (DSCSA) and adherence to federal regulations regarding pharmaceutical distribution. This opportunity is critical for ensuring the availability of essential medications for veterans' healthcare, reflecting the VA's commitment to quality and regulatory compliance in its supply chain. Interested vendors must submit their quotes, including a signed Standard Form 1449, a detailed price schedule in Excel format, and a state wholesale distributor license by April 9, 2025, with the estimated award date set for April 14, 2025. For further inquiries, vendors can contact Michael W McAlhaney at Michael.McAlhaney@va.gov or by phone at (913) 684-0134.